- Home
- PERF vs BDTX Comparison
PERF vs BDTX Comparison
Compare PERF & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PERF | BDTX |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.6M | 171.9M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PERF | BDTX |
|---|---|---|
| Price | $1.94 | $1.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.67 |
| AVG Volume (30 Days) | 155.9K | ★ 498.7K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.93 | N/A |
| Revenue Next Year | $9.44 | N/A |
| P/E Ratio | $26.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.24 | $1.60 |
| 52 Week High | $2.15 | $4.94 |
Technical Indicators
Market Signals| Indicator | PERF | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 62.77 | 42.63 |
| Support Level | $1.92 | $1.61 |
| Resistance Level | $1.94 | $2.28 |
| Average True Range (ATR) | 0.03 | 0.10 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 73.53 | 5.00 |
Price Performance
Historical ComparisonAbout PERF Perfect Corp.
Perfect Corp is engaged in the beauty and fashion tech revolution, providing omni-channel integrated solutions. The company runs a hybrid business model of direct consumer business (B2C business) and enterprise business (B2B business). For B2C businesses, the company offers six mobile apps under the "YouCam" suite, along with one online editing service tool, YouCam Online Editor, featuring AI and AR technologies. For B2B businesses, the company offers AI and AR-powered solutions tailored for the beauty and fashion industry. Geographically, the company has a presence in the United States, Americas-other, France, Japan, and Others. The company generates the majority of its revenue from the United States.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.